Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double‐blind, 12‐week, flexible‐dose, placebo‐controlled erectile dysfunction clinical trial

Associate Editor

[1]  M. Beneke,et al.  Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. , 2004, European urology.

[2]  R. Zoraghi,et al.  Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. , 2004, Molecular pharmacology.

[3]  K. Hatzimouratidis,et al.  Treatment Options for Erectile Dysfunction in Patients Failing Oral Drug Therapy , 2004 .

[4]  F. Montorsi,et al.  The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. , 2004, European urology.

[5]  H. Atiemo,et al.  Salvage of sildenafil failures referred from primary care physicians. , 2003, The Journal of urology.

[6]  M. Gleave,et al.  Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. , 2003, The Journal of urology.

[7]  H. Porst,et al.  Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. , 2003, Urology.

[8]  B. Trock,et al.  Clinical efficacy of sildenafil citrate and predictors of long-term response. , 2003, The Journal of urology.

[9]  W. Hellstrom,et al.  Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. , 2003, Urology.

[10]  I. Goldstein,et al.  Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. , 2003, Diabetes care.

[11]  C. Niederberger,et al.  Attitudes toward treatment of erectile dysfunction: Results from the males study , 2003 .

[12]  W. Hellstrom,et al.  Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. , 2002, Journal of andrology.

[13]  T. Costigan,et al.  Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. , 2002, The Journal of urology.

[14]  J. Urquhart,et al.  Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users , 2002, International Journal of Impotence Research.

[15]  P. Puri,et al.  Long-term outcome of the retained ureteral stump after lower pole heminephrectomy in duplex kidneys. , 2002, European urology.

[16]  N. Mabjeesh,et al.  Sildenafil versus the vacuum erection device: patient preference. , 2001, The Journal of urology.

[17]  P. Cuevas,et al.  The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil , 2001, International Journal of Impotence Research.

[18]  K. Andersson.  Pharmacology of penile erection. , 2001, Pharmacological reviews.

[19]  I. Goldstein,et al.  The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial , 2001, International Journal of Impotence Research.

[20]  R. Shabsigh,et al.  Efficacy, safety, and use of sildenafil in urologic practice. , 2001, Urology.

[21]  I. Osterloh,et al.  Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. , 2000, Urology.

[22]  J. Paladino.  Pharmacoeconomics of antimicrobial therapy. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  A. Burnett,et al.  Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. , 1999, The Journal of urology.

[24]  J. Rajfer,et al.  Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. , 1999, JAMA.

[25]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.

[26]  M. Shainline,et al.  Effectiveness and economic impact of antidepressant medications: a review. , 1997, The American journal of managed care.

[27]  C. Roehrborn,et al.  Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. , 1996, The Journal of urology.

[28]  A. L. A S T A I,et al.  Erectile dysfunction. , 2006, Harvard men's health watch.

[29]  S. Phillips,et al.  Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families , 2002 .

[30]  I. Goldstein,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.

[31]  NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. , 1993, JAMA.